GSK culls more res­pi­ra­to­ry drugs out of PhII as fo­cus shifts to can­cer

Glax­o­SmithK­line isn’t done with whit­tling down their res­pi­ra­to­ry drug and vac­cines port­fo­lios.

The phar­ma gi­ant un­cer­e­mo­ni­ous­ly scrapped two more res­pi­ra­to­ry drugs

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER